| Document |
Document Title |
|
WO/2022/223805A1 |
The present invention relates to compounds of formula (I), which are modulators of sortilin activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment...
|
|
WO/2022/221959A1 |
Disclosed herein are cyclopolyphosphazenes of formula (I): methods for the preparation thereof and uses thereof in adjuvant compositions.
|
|
WO/2022/222916A1 |
Provided are a compound for alcoholic liver injury, a preparation method, a composition, a food and the use. The compound has the following formula (I), wherein M is a divalent metal cation selected from Cu, Fe and Zn; A is selected from...
|
|
WO/2022/218250A1 |
Use of a compound represented by formula (I) or a stereoisomer, hydrate, metabolite, solvate, pharmaceutically acceptable salt, eutectic, or a composition thereof in preparation of a drug for treating pruritus. Also provided is a method ...
|
|
WO/2022/218415A1 |
A crystal form of an exatecan analog and a preparation method therefor, in particular, a crystal form of a compound as represented by formula (I) and a preparation method therefor. The present crystal form has good physical and chemical ...
|
|
WO/2022/218409A1 |
Disclosed in the present invention is a heptamethylcarbocyanine dye - crosslinked tetracyclic amine chelating agent conjugate, which comprises a cross-linking agent group L and a heptamethylcarbocyanine dye (HMCD) group that is coupled w...
|
|
WO/2022/220232A1 |
[Problem] To provide a fluorescent probe capable of detecting pancreatic cancer specifically. [Solution] A fluorescent probe for use in the detection of pancreatic cancer, which comprises a compound represented by general formula (I) or ...
|
|
WO/2022/215758A1 |
Provided are a lipid and a composition which are capable of effectively delivering an introduced compound such as a nucleic acid to, for instance, a target cell or tissue in vivo. The lipid according to the present invention is a lipid...
|
|
WO/2022/206587A1 |
A polypeptide compound having a structure shown in formula I, or a stereoisomer, mixture or pharmaceutically acceptable salt thereof. Experimental results show that the polypeptide compound can effectively exhibit high agonistic activity...
|
|
WO/2022/212367A1 |
Disclosed herein are anionic boron compounds. The anionic boron compounds include anionic boronic heterocycles, optionally ligated with carbenes. The anionic boron compounds are useful synthetic intermediates for boron heterocycles, as w...
|
|
WO/2022/204945A1 |
It relates to a composition for caring for keratin materials comprising in water: a) from 0.2 wt.% to 10 wt.% of a peptide of formula (I), relative to the total weight of the composition: R1-L-Tyr-L-Arg-R2 (I) wherein: R1 is an R3-C=O gr...
|
|
WO/2022/211624A1 |
The invention relates to self-assembling peptide (nano)fibers, hydrogels, and methods, uses and intermediate products and kits relating thereto. Provided is a method for providing peptide-based functionally modified (nano)fibers, compris...
|
|
WO/2022/208262A1 |
The invention relates to compounds of Formula I and pharmaceutically acceptable salts thereof wherein R1, R2, R3, p, q, q' and Ring A are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating corona...
|
|
WO/2022/202880A1 |
The purpose of the present invention is to provide: a lipid bilayer disc which can be produced easily, makes it possible to disperse a hydrophobic compound or the like in water satisfactorily, and has excellent transparency and stability...
|
|
WO/2022/199237A1 |
Provided are modified amino acids and an application thereof in ADC. The modified amino acids are phosphorylcholine group-modified amino acids represented by R1-L1-N(R2)-R3, wherein R1, L1, N, R2 and R3 are as defined herein. Further pro...
|
|
WO/2022/194399A1 |
The present invention relates to macrocyclic compounds of Formula (I) wherein Ar1, Ar2, R1, R2, R3, R4, and X are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharm...
|
|
WO/2022/194257A1 |
A compound of formula (II) and a preparation method therefor, and a method for preparing a camptothecin derivative and an antibody drug conjugate from the compound of formula (II). The preparation method for the compound of formula (II) ...
|
|
WO/2022/193038A1 |
Disclosed are a [18F]AlF labeled PSMA targeting molecular probe and a preparation method therefor, wherein the structural formula is as follows: 18F is used as a radioactive labeled nuclide, and a PSMA targeting molecular probe is labele...
|
|
WO/2022/190100A1 |
Disclosed herein are levodopa prodrug compounds and methods for their use. Further disclosed herein are liquid pharmaceutical formulations comprising a levodopa-tyrosine conjugate and a stabilizer, wherein the liquid pharmaceutical formu...
|
|
WO/2022/190486A1 |
The present invention provides, as a novel compound that can be utilized for efficient synthesis or the like of a polypeptide comprising various amino acids, a silane-containing condensed cyclic dipeptide compound represented by formula ...
|
|
WO/2022/188877A1 |
The present invention relates to the technical field of medicines. Disclosed are a synthetic peptide and an application thereof. The chemical formula of the synthetic peptide is (Gly)x-(beta-Ala-L-His)y-(Gly)z, (Gly)x-(beta-Ala-L-1-Methy...
|
|
WO/2022/188878A1 |
Provided is a multifunctional polypeptide, consisting of one or more of at least one Pro-Ala-Lys, Ala-Lys-Pro, Lys-Ala-Pro and a fragment thereof and a derived peptide, there being carnosine, anserine or ophidine at the C-terminus and/or...
|
|
WO/2022/186290A1 |
The present invention addresses the problem of providing a peptide having excellent dipeptidyl peptidase-IV (DPP-IV) inhibitory activity. An oligopeptide including any of the sequences described in (a) to (h) below. These oligopeptides m...
|
|
WO/2022/183993A1 |
Provided is a compound targeting a prostate specific membrane antigen (PSMA). The compound has a structure as represented by formula (I), wherein R1 is a compound targeting a prostate specific membrane antigen; L1 is -(X)n-(CH 2)m-(Y)q-,...
|
|
WO/2022/187491A1 |
Provided herein are pharmaceutical compositions including compounds having Formula (I) in an effective amount to inhibit cysteine protease as well as methods of using thereof.
|
|
WO/2022/180410A1 |
The present invention provides a series of tripeptides according to the compound of formula (I) that inhibit the interaction of both HIF-1α and HIF-2α with HIf-1 β by binding to the PAS-B domain of the α subunit of HIF. The tripeptid...
|
|
WO/2022/178592A1 |
The disclosure provides methods for the solid phase synthesis of glutamate-urea-lysine derived (GUL derived) prostate-specific membrane antigen (PSMA) targeting conjugates. The disclosure also relates to key intermediates of this process...
|
|
WO/2022/174058A1 |
Disclosed are peptides having the structure according to formula (la) or (lb) or (II): wherein NH-Q-C(O) is a peptide chain optionally comprising an amino acid residue having a sidechain covalently bonded to Z2; Z1 is a moiety comprising...
|
|
WO/2022/171115A1 |
Disclosed in the present invention is a camptothecin derivative for antibody drug conjugate (ADC) preparation. In particular, the present invention provides a camptothecin derivative, and a preparation method therefor and an application ...
|
|
WO/2022/168939A1 |
Provided is a ceramide synthase gene expression promoting agent in which a prescribed dipeptide is employed as a main ingredient for bringing about a function, and which is capable of increasing the expression level of a ceramide synthas...
|
|
WO/2022/165606A1 |
LIN28 is an RNA binding protein that binds and inhibits the expression and maturation of Iet7 microRNA that carries key tumor suppressor functions. Thus, LIN28 is a feasible and effective molecular target for directed inhibition with the...
|
|
WO/2022/168894A1 |
[Problem] To provide a new material that prevents adhesion of pollutants by forming a film on a cloth or paper surface, and that prevents the cloth and paper surfaces from being polluted by the pollutants. [Solution] An anti-pollution ma...
|
|
WO/2022/168872A1 |
A cell culture microcarrier is provided which can suppress damage of microcarriers in the cell culture process and which can improve the cell culture efficiency. This cell culture microcarrier is provided with substrate particles and a...
|
|
WO/2022/167087A1 |
The invention provides compounds of formula (I), that are peptidase enhanced cytotoxics. The invention further provides pharmaceutical compositions comprising the compounds, and the use of the compounds or pharmaceutical compositions as ...
|
|
WO/2022/166719A1 |
A CA4 derivative, a conjugate or pharmaceutically acceptable salt thereof, a preparation method therefor, and use thereof in prevention or treatment of cancer. The conjugate can specifically bind to a receptor highly expressed in a tumor...
|
|
WO/2022/167664A1 |
The present invention relates to the field of compounds intended for the treatment of cancer. Selectivity of these compounds is gained through the presence of a specific tetrapeptidic moiety allowing selective release of the drug. The dr...
|
|
WO/2022/168871A1 |
Provided is a cell culture microcarrier capable of suppressing aggregation of a microcarrier due to cell clumps and enhancing the efficiency of culturing cells. This cell culture microcarrier is provided with a base particle and a coat...
|
|
WO/2022/162030A1 |
The present invention therefore relates to peptides of synthetic origin andbiologically active in inhibiting the binding between VEGFR-1 and VEGFR-2receptors and their ligands, and use thereof as a medicament.The use as a medicament of a...
|
|
WO/2022/156693A1 |
A compound represented by formula I containing an N-(substituted sulfonyl) acetamide structure, a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, and an application thereof as a viral protease inhibitor in the prepa...
|
|
WO/2022/156190A1 |
The present invention provides an antihypertensive peptide, a polyethylene glycol modified antihypertensive peptide, and preparation methods therefor. The antihypertensive peptide of the present invention comprises at least one polypepti...
|
|
WO/2022/149584A1 |
The present invention provides a peptide having a fluoroalkyl group as a side chain. The present invention pertains to a peptide in which two or more amino acids are peptide-bonded, wherein at least one of the amino acid residues constit...
|
|
WO/2022/150362A1 |
Provided herein are compounds and compositions that are reversible agonists of the PDZ3 domain of PSD-95. Methods of their use in treating conditions of neural stress, inflammation, and viability are also provided.
|
|
WO/2022/144293A1 |
The invention relates to a process for producing readily filterable particles of DL/LD-methionylmethionine, characterized in that a stream of aqueous solution or suspension containing DL/LD-methionylmethionine alkali metal salt is mixed ...
|
|
WO/2022/138891A1 |
The present invention addresses the problem of providing a method for producing a high-purity peptide compound with high efficiency and high yield. It is found that the problem can be solved by supporting a peptide on a resin for solid-p...
|
|
WO/2022/138953A1 |
[Problem] To provide a method by which a lipid peptide compound and a salt thereof can be produced with a higher yield and a higher purity than conventional production methods. [Solution] A method for producing a lipid peptide compound r...
|
|
WO/2022/133588A1 |
The present disclosure provides compounds of formula (I) and methods for inhibiting a virus infection, such as a Baltimore Group IV RNA virus infection, such as rhinovirus, coxsackievirus, norovirus and coronavirus. Aspects of the presen...
|
|
WO/2022/137357A1 |
The present invention addresses the problem of providing a synthetic culture medium free from animal-derived components. More particularly, the present invention addresses the problem of providing a culture medium that contains a peptide...
|
|
WO/2022/138957A1 |
[Problem] To provide a practical method for producing a lipidic peptide compound, the method enabling a lipidic peptide compound to be mass produced inexpensively without the need for complicated operations. [Solution] A lipidic peptide ...
|
|
WO/2022/136586A1 |
The present invention relates to the field of compounds intended for the treatment of cancer. Selectivity of these compounds is gained through the presence of a specific tetrapeptidic moiety allowing selective release of the drug. The dr...
|
|
WO/2022/133069A1 |
The present disclosure is directed, in part, to compounds, or pharmaceutically acceptable salts thereof, for modulating the activity of Matriptase 2 ("Mat-2"), or a mutant thereof. The present disclosure also provides pharmaceutically ac...
|
